Lv55
1590 积分 2022-06-08 加入
Cardiovascular risk in diabetes mellitus: epidemiology, assessment and prevention
19天前
已完结
Novel GLP-1-based Medications for Type 2 Diabetes and Obesity
19天前
已完结
Efficacy and safety of tirzepatide added to basal insulin in patients with type 2 diabetes in China (SURPASS-CN-INS): a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial
22天前
已完结
Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial
22天前
已完结
Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials
22天前
已完结
Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes
22天前
已完结
Cardiovascular and Kidney Outcomes and Mortality With Long-Acting Injectable and Oral Glucagon-Like Peptide 1 Receptor Agonists in Individuals With Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Trials
22天前
已完结
Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes
2个月前
已完结
Mazdutide versus placebo in Chinese adults with type 2 diabetes
2个月前
已完结
Efficacy and safety of cAMP-biased GLP-1 receptor agonist ecnoglutide versus dulaglutide in patients with type 2 diabetes and elevated glucose concentrations on metformin monotherapy (EECOH-2): a 52-week, multicentre, open-label, non-inferiority, randomised, phase 3 trial
2个月前
已完结
皖公网安备34019202002308
